Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Human antibodies against noncircumsporozoite proteins block Plasmodium falciparum parasite development in hepatocytes
Amanda Fabra-García, Annie S.P. Yang, Marije C. Behet, Zen Yap, Youri van Waardenburg, Swarnendu Kaviraj, Kjerstin Lanke, Geert-Jan van Gemert, Matthijs M. Jore, Teun Bousema, Robert W. Sauerwein
Amanda Fabra-García, Annie S.P. Yang, Marije C. Behet, Zen Yap, Youri van Waardenburg, Swarnendu Kaviraj, Kjerstin Lanke, Geert-Jan van Gemert, Matthijs M. Jore, Teun Bousema, Robert W. Sauerwein
View: Text | PDF
Research Article Infectious disease Vaccines

Human antibodies against noncircumsporozoite proteins block Plasmodium falciparum parasite development in hepatocytes

  • Text
  • PDF
Abstract

Sporozoite-based approaches currently represent the most effective vaccine strategies for induction of sterile protection against Plasmodium falciparum (Pf) malaria. Clinical development of subunit vaccines is almost exclusively centered on the circum-sporozoite protein (CSP), an abundantly expressed protein on the sporozoite membrane. Anti-CSP antibodies are able to block sporozoite invasion and development in human hepatocytes and subsequently prevent clinical malaria. Here, we have investigated whether sporozoite-induced human antibodies with specificities different from CSP can reduce Pf-liver stage development. IgG preparations were obtained from 12 volunteers inoculated with a protective immunization regime of whole sporozoites under chloroquine prophylaxis. These IgGs were depleted for CSP specificity by affinity chromatography. Recovered non-CSP antibodies were tested for sporozoite membrane binding and for functional inhibition of sporozoite invasion of a human hepatoma cell line and hepatocytes both in vitro and in vivo. Postimmunization IgGs depleted for CS specificity of 9 of 12 donors recognized sporozoite surface antigens. Samples from 5 of 12 donors functionally reduced parasite-liver cell invasion or development using the hepatoma cell line HC-04 and FRG-huHep mice containing human liver cells. The combined data provide clear evidence that non-CSP proteins, as yet undefined, do represent antibody targets for functional immunity against Pf parasites responsible for malaria.

Authors

Amanda Fabra-García, Annie S.P. Yang, Marije C. Behet, Zen Yap, Youri van Waardenburg, Swarnendu Kaviraj, Kjerstin Lanke, Geert-Jan van Gemert, Matthijs M. Jore, Teun Bousema, Robert W. Sauerwein

×

Figure 2

Sporozoite surface recognition before immunization and after depletion of CSP-specific antibodies.

Options: View larger image (or click on image) Download as PowerPoint
Sporozoite surface recognition before immunization and after depletion o...
(A) Dose-dependent reactivity of sporozoite-specific polyclonal IgG with specificities different from CSP. Each line represents an individual volunteer, except for orange, which represented the reactivity of a pool of preimmunization samples (n = 12). Blue shows volunteer 1, with the strongest binding.Black shows volunteers with medium binding, and gray shows volunteers with low binding. Each sample was tested at 3 concentrations in duplicate, and a 2-way ANOVA was performed to determine dose response. There was an overall statistically significant dose response obtained when testing the IgGs at different concentrations (***P < 0.001). (B) Immunofluorescence with pool of preimmune samples and postimmunization depleted antibodies of volunteer 1 by microscopy. Red shows the reactivity of non-CSP antibodies, green shows CSP staining using mAb 3SP2, and blue shows nuclei staining with DAPI. Scale bar: 25 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts